Docetaxel (NSC-628503), Cisplatin (NSC-119875), and 5-Fluorouracil (NSC-19893) Induction Chemotherapy Followed by Accerlerated Fractionation/Concomitant Boost Radiation and Concurrent Single Agent Cisplatin (NSC-119875), in Patients with Advanced Squamous Cell Head and Neck Cancer

Pts must have previously untreated histologically proven dx of SCCHN (excluding lip, nasopharynx, paranasal sinus and salivary gland) based on bx or FNA of the primary lesion or neck mass. Pts must have Stage III or IV dz w/ no evidence of distant met. All pts must have neg CXR w/i 28 days prior to reg (note: Pts must have been determined to be appropriate for definitive RT w/ curative intent). Pts with unknown primary site are not elig. Dz must be documented by CT or MRI w/i 42 days prior to reg. Pts must not have myocardial infarction w/i the last 3 mo or not unstable or uncontrolled angina and not active systemic infection. PS 0 - 1. Pts must be evaluated by Radiation & Medical Oncologist w/i 28 day; pts must undergo evaluation by a H&N surgeon, to include, when appropriate, an exam under anesthesia w/ direct laryngoscopy, nasopharyngscopy, esophagoscopy, and bronchoscopy w/i 28 days prior to reg; and pts with teeth must be evaluated by dentistry w/i 28 days prior to reg. No prior therapeutic srg and pts must not have had RT or chemo of any kind for any reason. Pts must have adequate renal and hepatic function. Pts must have adequate hematologic values. Pregnant or nursing women may not elig.